Tocilizumab, a humanized monoclonal antibody directly targeting the IL-6R, significantly improves lung function in COVID-19 and was also reported to be efficient in case reports of sarcoidosis-associated posterior uveitis [130,131]. The gene discussed is IL6R; the disease is sarcoidosis.